Patents by Inventor Masayoshi Miyagawa
Masayoshi Miyagawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230287004Abstract: The present invention provides the following compounds having anti-viral activity. A1 is CR1AR1B, S or O; A2 is CR2AR2B, S or O; A3 is CR3AR3B, S or O; A4 is CR4AR4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A1, is 1 or 2; R1A and R1B are each independently hydrogen, halogen, alkyl, or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B are each independently hydrogen, halogen, alkyl, or the like; R4A and R4B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B may be taken together to form non-aromatic carbocycle or non-aromatic heterocycle; X is CH2, S or O; R1 is each independently halogen, hydroxy, or the like; m is any integer of 0 to 2; and n is any integer of 1 to 2.Type: ApplicationFiled: December 13, 2022Publication date: September 14, 2023Applicant: Shionogi & Co., Ltd.Inventors: Makoto KAWAI, Kenji TOMITA, Toshiyuki AKIYAMA, Azusa OKANO, Masayoshi MIYAGAWA
-
Publication number: 20220281890Abstract: The present invention provides a pharmaceutical composition containing the following compound having antiviral action: P is hydrogen or a group to form a prodrug; A1 is CR1AR1B, S or O; A2 is CR2AR2B, S or O; A3 is CR3AR3B, S or O; A4 is each independently CR4AR4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A4, is 1 or 2; R1A and R1B are each independently hydrogen, halogen, alkyl, or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B are each independently hydrogen, halogen, alkyl, or the like; R4A and R4B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B may be taken together with an adjacent carbon atom to form non-aromatic carbocycle or non-aromatic heterocycle; R1 is fluorine; m is any integer of 1 to 2; and n is any integer of 1 to 2.Type: ApplicationFiled: March 8, 2022Publication date: September 8, 2022Applicant: Shionogi & Co., Ltd.Inventors: Makoto KAWAI, Kenji TOMITA, Toshiyuki AKIYAMA, Azusa OKANO, Masayoshi MIYAGAWA
-
Publication number: 20200361958Abstract: The present invention provides a pharmaceutical composition containing the following compound having antiviral action: wherein each of the symbols is defined in the specification.Type: ApplicationFiled: July 24, 2020Publication date: November 19, 2020Applicant: Shionogi & Co., Ltd.Inventors: Makoto KAWAI, Kenji TOMITA, Toshiyuki AKIYAMA, Azusa OKANO, Masayoshi MIYAGAWA
-
Publication number: 20200339565Abstract: The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.Type: ApplicationFiled: November 15, 2019Publication date: October 29, 2020Applicant: Shionogi & Co., Ltd.Inventors: Chika TAKAHASHI, Hidenori MIKAMIYAMA, Toshiyuki AKIYAMA, Kenji TOMITA, Yoshiyuki TAODA, Makoto KAWAI, Kosuke ANAN, Masayoshi MIYAGAWA, Naoyuki SUZUKI
-
Publication number: 20200283455Abstract: The present invention provides the following compounds having anti-viral activity. A1 is CR1AR1B, S or O; A2 is CR2AR2B, S or O; A3 is CR3AR3B, S or O; A4 is CR4AR4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A1, is 1 or 2; R1A and R1B are each independently hydrogen, halogen, alkyl, or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B are each independently hydrogen, halogen, alkyl, or the like; R4A and R4B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B may be taken together to form non-aromatic carbocycle or non-aromatic heterocycle; X is CH2, S or O; R1 is each independently halogen, hydroxy, or the like; m is any integer of 0 to 2; and n is any integer of 1 to 2.Type: ApplicationFiled: March 23, 2020Publication date: September 10, 2020Applicant: Shionogi & Co., Ltd.Inventors: Makoto KAWAI, Kenji TOMITA, Toshiyuki AKIYAMA, Azusa OKANO, Masayoshi MIYAGAWA
-
Publication number: 20190248785Abstract: The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.Type: ApplicationFiled: November 19, 2018Publication date: August 15, 2019Applicant: Shionogi & Co., Ltd.Inventors: Chika TAKAHASHI, Hidenori MIKAMIYAMA, Toshiyuki AKIYAMA, Kenji TOMITA, Yoshiyuki TAODA, Makoto KAWAI, Kosuke ANAN, Masayoshi MIYAGAWA, Naoyuki SUZUKI
-
Publication number: 20190169206Abstract: The present invention provides a pharmaceutical composition containing the following compound having antiviral action: wherein each of the symbols is defined in the specification.Type: ApplicationFiled: August 9, 2017Publication date: June 6, 2019Applicant: Shionogi & Co., Ltd.Inventors: Makoto KAWAI, Kenji TOMITA, Toshiyuki AKIYAMA, Azusa OKANO, Masayoshi MIYAGAWA
-
Publication number: 20190112315Abstract: The present invention provides the following compounds having anti-viral activity. A1 is CR1AR1B, S or O; A2 is CR2AR2B, S or O; A3 is CR3AR3B, S or O; A4 is CR4AR4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A1, is 1 or 2; R1A and R1B are each independently hydrogen, halogen, alkyl, or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B are each independently hydrogen, halogen, alkyl, or the like; R4A and R4B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B may be taken together to form non-aromatic carbocycle or non-aromatic heterocycle; X is CH2, S or O; R1 is each independently halogen, hydroxy, or the like; m is any integer of 0 to 2; and n is any integer of 1 to 2.Type: ApplicationFiled: December 17, 2018Publication date: April 18, 2019Applicant: Shionogi & Co., Ltd.Inventors: Makoto KAWAI, Kenji TOMITA, Toshiyuki AKIYAMA, Azusa OKANO, Masayoshi MIYAGAWA
-
Patent number: 10202379Abstract: The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.Type: GrantFiled: August 14, 2017Date of Patent: February 12, 2019Assignee: SHIONOGI & CO., LTD.Inventors: Chika Takahashi, Hidenori Mikamiyama, Toshiyuki Akiyama, Kenji Tomita, Yoshiyuki Taoda, Makoto Kawai, Kosuke Anan, Masayoshi Miyagawa
-
Publication number: 20180118760Abstract: The present invention provides the following compounds having anti-viral activity. A1 is CR1AR1B, S or O; A2 is CR2AR2B, S or O; A3 is CR3AR3B, S or O; A4 is CR4AR4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A1, is 1 or 2; R1A and R1B are each independently hydrogen, halogen, alkyl, or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B are each independently hydrogen, halogen, alkyl, or the like; R4A and R4B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B may be taken together to form non-aromatic carbocycle or non-aromatic heterocycle; X is CH2, S or O; R1 is each independently halogen, hydroxy, or the like; m is any integer of 0 to 2; and n is any integer of 1 to 2.Type: ApplicationFiled: April 27, 2016Publication date: May 3, 2018Applicant: Shionogi & Co., Ltd.Inventors: Makoto KAWAI, Kenji TOMITA, Toshiyuki AKIYAMA, Azusa OKANO, Masayoshi MIYAGAWA
-
Publication number: 20170349587Abstract: The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.Type: ApplicationFiled: August 14, 2017Publication date: December 7, 2017Applicant: Shionogi & Co., Ltd.Inventors: Chika Takahashi, Hidenori Mikamiyama, Toshiyuki Akiyama, Kenji Tomita, Yoshiyuki Taoda, Makoto Kawai, Kosuke Anan, Masayoshi Miyagawa
-
Patent number: 9758515Abstract: The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.Type: GrantFiled: December 5, 2014Date of Patent: September 12, 2017Assignee: SHIONOGI & CO., LTD.Inventors: Chika Takahashi, Hindenori Mikamiyama, Toshiyuki Akiyama, Kenji Tomita, Yoshiyuki Taoda, Makoto Kawai, Kosuke Anan, Masayoshi Miyagawa, Naoyuki Suzuki
-
Publication number: 20170253607Abstract: The present invention provides useful compounds for HIV protease inhibitor.Type: ApplicationFiled: September 10, 2015Publication date: September 7, 2017Applicant: Shionogi & Co., Ltd.Inventors: Takashi KAWASUJI, Hidenori MIKAMIYAMA, Naoyuki SUZUKI, Koji MASUDA, Hideki SUGIMOTO, Azusa OKANO, Miho YOSHIDA, Shuichi SUGIYAMA, Kentarou ASAHI, Iori KOZONO, Keisuke MIYAZAKI, Hiroki OZASA, Masayoshi MIYAGAWA
-
Publication number: 20150111854Abstract: The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.Type: ApplicationFiled: December 5, 2014Publication date: April 23, 2015Inventors: Chika TAKAHASHI, Hindenori MIKAMIYAMA, Toshiyuki AKIYAMA, Kenji TOMITA, Yoshiyuki TAODA, Makoto KAWAI, Kosuke ANAN, Masayoshi MIYAGAWA, Naoyuki SUZUKI
-
Patent number: 8987441Abstract: The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.Type: GrantFiled: September 21, 2011Date of Patent: March 24, 2015Assignee: Shionogi & Co., Ltd.Inventors: Chika Takahashi, Hidenori Mikamiyama, Toshiyuki Akiyama, Kenji Tomita, Yoshiyuki Taoda, Makoto Kawai, Kosuke Anan, Masayoshi Miyagawa, Naoyuki Suzuki
-
Publication number: 20130197219Abstract: The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.Type: ApplicationFiled: September 21, 2011Publication date: August 1, 2013Inventors: Chika Takahashi, Hidenori Mikamiyama, Toshiyuki Akiyama, Kenji Tomita, Yoshiyuki Taoda, Makoto Kawai, Kosuke Anan, Masayoshi Miyagawa, Naoyuki Suzuki
-
Publication number: 20120277238Abstract: The present invention provides a compound which indicates a histamine H4 receptor modulating activity. A compound represented by a formula (I): wherein A ring is a ring represented by the following formula: wherein R1 is substituted or unsubstituted alkyl, etc., W is —O—, etc., n is an integer of 0 to 6; X is —N(R7)— or —O—; R7 is hydrogen, substituted or unsubstituted alkyl, etc.; Y is —C(R8)? or —N?; R8 is hydrogen, substituted or unsubstituted alkyl, etc.; Z is ?O, ?S, etc.; B ring is a ring represented by the following formula: wherein R10 is each independently substituted or unsubstituted alkyl, halogen, hydroxy, substituted or unsubstituted alkyloxy, substituted or unsubstituted amino; R11, R12a and R12b are each independently hydrogen or substituted or unsubstituted alkyl, etc.; p is an integer of 0 to 4, or its pharmaceutically acceptable salt, or a solvate thereof.Type: ApplicationFiled: July 29, 2010Publication date: November 1, 2012Applicant: Shionogi & Co., LtdInventors: Yuuki Tachibana, Masayoshi Miyagawa, Tsutomu Masuda, Tsuyoshi Hasegawa